Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 28:12:735044.
doi: 10.3389/fphar.2021.735044. eCollection 2021.

Sirtuin Modulators in Cellular and Animal Models of Human Diseases

Jun Young Hong  1 , Hening Lin  1   2
Affiliations
Review

Sirtuin Modulators in Cellular and Animal Models of Human Diseases

Jun Young Hong et al. Front Pharmacol. .

Abstract

Sirtuins use NAD+ to remove various acyl groups from protein lysine residues. Through working on different substrate proteins, they display many biological functions, including regulation of cell proliferation, genome stability, metabolism, and cell migration. There are seven sirtuins in humans, SIRT1-7, each with unique enzymatic activities, regulatory mechanisms, subcellular localizations, and substrate scopes. They have been indicated in many human diseases, including cancer, neurodegeneration, microbial infection, metabolic and autoimmune diseases. Consequently, interests in development of sirtuin modulators have increased in the past decade. In this brief review, we specifically summarize genetic and pharmacological modulations of sirtuins in cancer, neurological, and cardiovascular diseases. We further anticipate this review will be helpful for scrutinizing the significance of sirtuins in the studied diseases.

Keywords: SIRT1; SIRT2; activator; cancer; cardiovacsular diseases; inhibitor; neurodeganaration; sirtuin.

PubMed Disclaimer

Conflict of interest statement

HL is a founder and consultant for Sedec Therapeutics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Schematic summary of sirtuin deacylation mechanism. (B) Schematic summary of mechanism-based inhibition of sirtuin
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abril Y. L. N., Fernandez I. R., Hong J. Y., Chiang Y. L., Kutateladze D. A., Zhao Q., et al. (2021). Pharmacological and Genetic Perturbation Establish SIRT5 as a Promising Target in Breast Cancer. Oncogene 40, 1644–1658. 10.1038/s41388-020-01637-w - DOI - PMC - PubMed
    1. Aksoy P., White T. A., Thompson M., Chini E. N. (2006). Regulation of Intracellular Levels of NAD: a Novel Role for CD38. Biochem. Biophys. Res. Commun. 345, 1386–1392. 10.1016/j.bbrc.2006.05.042 - DOI - PubMed
    1. Alcendor R. R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., et al. (2007). Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart. Circ. Res. 100, 1512–1521. 10.1161/01.RES.0000267723.65696.4a - DOI - PubMed
    1. Alcendor R. R., Kirshenbaum L. A., Imai S., Vatner S. F., Sadoshima J. (2004). Silent Information Regulator 2alpha, a Longevity Factor and Class III Histone Deacetylase, Is an Essential Endogenous Apoptosis Inhibitor in Cardiac Myocytes. Circ. Res. 95, 971–980. 10.1161/01.RES.0000147557.75257.ff - DOI - PubMed
    1. Alhazzazi T. Y., Kamarajan P., Joo N., Huang J. Y., Verdin E., D'Silva N. J., et al. (2011). Sirtuin-3 (SIRT3), a Novel Potential Therapeutic Target for Oral Cancer. Cancer 117, 1670–1678. 10.1002/cncr.25676 - DOI - PMC - PubMed